Oppenheimer raised the firm’s price target on Monopar Therapeutics (MNPR) to $115 from $77 and keeps an Outperform rating on the shares. Following the publication of peer-reviewed Letter to the Editor in the Journal of Hepatology that, in the firm’s view, convincingly corrected the AstraZenca (AZN) error, Oppenheimer sees a straight path to NDA submission in Q1 2026 that includes potential additional data around AASLD, a Type D meeting with the FDA along with a patient advocacy led meeting on January 29 EL-PFDD. To reflect the firm’s increased confidence that the re-analysis supports ALXN1840’s ability to effectively eliminate copper, Oppenheimer is increasing the multiple to 8x from 7x on $244M net product revenues in 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright
- Monopar Therapeutics price target raised to $85 from $60 at Chardan
- Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler
- Monopar Therapeutics Announces Underwriting Agreement for Stock Sale
- Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings